---
title: "Webinar - MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases"
description: "Webinar - MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases - Jan 2026"
image: https://info.edifydigitalmedia.com/hubfs/Evotec-webinar-Feature-Image-366x250px.jpg
---

[![DDW-Logo](https://info.edifydigitalmedia.com/hs-fs/hubfs/DDW-Logo.png?width=239&height=121&name=DDW-Logo.png "DDW-Logo")](https://www.edifydigitalmedia.com/)

![Evotec-webinar-Landing-Page-Banner-290126\_1425px](https://info.edifydigitalmedia.com/hubfs/Evotec-webinar-Landing-Page-Banner-290126_1425px.jpg "Evotec-webinar-Landing-Page-Banner-290126_1425px")

Webinar  
MS-based targeted proteomics: A cornerstone to progress drug development through preclinical and clinical phases

 

 

 

![DDW\_Evotec\_Event\_Logo\_400px\_cropped](https://info.edifydigitalmedia.com/hs-fs/hubfs/DDW_Evotec_Event_Logo_400px_cropped.jpg?width=400&height=112&name=DDW_Evotec_Event_Logo_400px_cropped.jpg)

---

 

![Yvan-Eb-Levadoux\_speaker\_image\_200px](https://info.edifydigitalmedia.com/hubfs/Yvan-Eb-Levadoux_speaker_image_200px.jpg "Yvan-Eb-Levadoux_speaker_image_200px")

Mass spectrometry-based targeted proteomics supports each step of drug development, from early discovery to preclinical phases and even clinical phases. 

End-to-end solutions range from sourcing and managing samples to standardised preparation, cutting-edge mass spectrometry, and advanced in-house data analysis. What’s more, tailored MS-based assays enable high resolution or high throughput without compromising on accuracy, sensitivity, specificity, or robustness. The number of targets can range from a few to several dozens of proteins from a wide range of matrices: cell lines, animal and human biofluids, tissues, and blood cell sorting.

This webinar, hosted by DDW and supported by Evotec, will cover a diverse set of applications to illustrate how tailored and targeted proteomics fulfils scientific – and even regulatory – requirements at each step of drug development. It will also cover how to deal with low material inputs or low-abundant proteins.

Whether you're exploring biomarker options in early discovery or assessing drug candidates in preclinical or clinical stage, this webinar will equip you with actionable insights and real-world examples to accelerate your discovery efforts.

You will learn:

- How targeted proteomics supports different stages of drug development, including scientific and regulatory requirements
- More specifically, how fit-for-purpose targeted proteomics fulfils project specificities (sample preparation, LC/MS platforms and data analysis)
- Practical applications and case examples, such as working with low-input samples or detecting low-abundance proteins
  
  **Register for free and watch the webinar on-demand now!**
  
  About the speaker:

Yvan Eb Levadoux, PhD, has over ten years of proteomics experience, specialising in targeted mass spectrometry workflows. He has developed FDA and ICH M10-compliant quantitative proteomics methods, including one validated as a primary endpoint in a Phase I clinical trial.

### Watch the Webinar

## Copyright 2022 Drug Discovery World. All Rights Reserved Privacy Policy & Cookies | Contact | Terms & Conditions